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 ABSTRACT 
Chronic progressive external ophthalmoplegia (CPEO) is common in 
mitochondrial disorders, being frequently associated with multiple mtDNA 
deletions. The onset is typically in adulthood and affected subjects may also 
present general muscle weakness. The underlying genetic defects comprise 
autosomal dominant or recessive mutations in several nuclear genes, most of 
which play a role in mtDNA replication. Next generation sequencing led to the 
identification of compound heterozygous RNASEH1 mutations in two simplex 
cases and a homozygous mutation in four siblings. RNASEH1, encoding 
ribonuclease H1, is an endonuclease present in both nucleus and mitochondria, 
which digests the RNA component of RNA/DNA hybrids. Unlike mitochondria, 
the nucleus harbours a second ribonuclease H activity (RNAseH2). All affected 
individuals started with CPEO and exercise intolerance in their twenties, 
followed by muscle weakness, dysphagia, and spino-cerebellar signs with 
impaired gait coordination, dysmetria and dysarthria. Ragged-red and COX 
negative fibres were observed in muscle biopsies of affected subjects’ together 
with impaired activity of various mitochondrial respiratory chain complexes. 
Western blot analysis showed the virtual absence of the RNAseH1 protein in 
total lysate from mutant fibroblasts. By an in vitro assay, we demonstrated that 
mutant RNAseH1 variants have reduced capability to remove the RNA from 
RNA/DNA hybrids, confirming their pathogenic role. Since an increasing 
amount of evidence indicates the presence of RNA primers during mtDNA 
replication, this result may also explain the accumulation of mtDNA deletions 
and underscores the importance of RNAseH1 for mtDNA maintenance. 	  
  
REPORT 
Accumulation of multiple mtDNA deleted species (ΔmtDNA) in skeletal muscle and 
brain is the molecular hallmark of a group of autosomal recessive or dominant 
mitochondrial encephalomyopathies, characterized by chronic, progressive external 
ophthalmoplegia (CPEO) caused by mutations in nuclear genes affecting the integrity 
of the mitochondrial genome. This condition is part of a spectrum of clinically and 
genetically heterogeneous disorders of intergenomic communication, which also 
includes mtDNA depletion syndromes. An increasing number of genes have been 
associated with this category of mitochondrial disorders, encoding components of 
mtDNA replisome, mitochondrial deoxynucleotide supply, mitochondrial dynamics 
and quality control, and also proteins of still unknown function1,2. Recently, mutations 
in DNA2 [MIM 601810]3 and MGME1 [MIM 615076]4, encoding exonucleases 
involved in mtDNA repair or maturation, have been associated with CPEO/ΔmtDNA. 
We show here that mutations in RNASEH1 [MIM 604123], encoding an endonuclease 
specific to RNA-DNA double stranded hybrids5, cause the same syndrome. We 
studied two singleton subjects (S1, S2) and four affected siblings (S3-6) (Figure 1A). 
S1 and S2 developed juvenile-onset CPEO, muscle weakness and wasting, peripheral 
sensory-motor neuropathy, progressive spino-cerebellar ataxia and pyramidal signs. 
Involvement of respiratory muscles explains the severe nocturnal 
dyspnoea/orthopnoea in S1. CPEO occurred later in S3-6 siblings, but symptoms and 
progression were similar, with CPEO, dysphagia and respiratory impairment. S3, S4 
and S5 died at 60, 70 and 63 years respectively; S6 is now 65 years old, wheelchair-
bound, PEG-fed and under non-invasive ventilation. All affected individuals showed 
cerebellar involvement, secondary to MRI-proven cerebellar atrophy (Figure 1B). In 
 addition to CPEO, affected subjects displayed a number of peculiar features, e.g. 
exquisite involvement of respiratory muscles and progressive ataxia due to severe 
involvement of the spino-cerebellar pathways and cerebellar atrophy, which could be 
useful clues for diagnosis. Muscle biopsies of all six subjects showed numerous 
ragged-red, intensely SDH-positive, COX-negative fibres (Figure 1C). Electron 
microscopy on S2 muscle showed extremely elongated, hyperfused mitochondria 
(Figure 1D). Spectrophotometric analysis of S1 and S2 muscle homogenates, and S2 
myoblasts, showed partially reduced complex I and IV activities, whereas values were 
normal in S1 fibroblasts. Detailed clinical and biochemical descriptions of the 
affected individuals are reported as supplemental case reports. Informed consent for 
participation in this study was obtained from all investigated subjects, in agreement 
with the Declaration of Helsinki and approved by the Ethical Committees of the 
Centers where biological samples were obtained. Southern-blot analysis showed 
multiple ΔmtDNAs in muscle from S1-4 and S6 (no muscle DNA was available for 
S5) (Figure 1E). The mtDNA copy number was unchanged (105% in S2) or increased 
(300% in S1) in skeletal muscle, while significant mtDNA depletion (16%) was 
detected in S2 myoblasts by qPCR (Figure 1F).  
In order to identify the underlying genetic cause in our probands, we first ruled out 
several genes involved in CPEO/ΔmtDNA syndromes by Sanger’ sequencing. We 
then performed whole-exome sequencing on S1 DNA; after filtering steps (Tables S1 
and S2), we searched for homozygous or compound heterozygous variants, according 
to a recessive trait. From selected novel or rare variants in genes encoding known or 
predicted mitochondrial proteins, we zeroed on two changes in RNASEH1 (RefSeq 
NM_002936.4), a c.424G>A (p.Val142Ile) on the paternal allele, and a nonsense 
c.469C>T (p.Arg157*) on the maternal allele. Next, we screened RNASEH1 on a 
 cohort of 40 genetically undefined CPEO/ΔmtDNA individuals and identified 
compound heterozygous mutations c.424G>A (p.Val142Ile) and c.554C>T 
(p.Ala185Val) in S2. S3 was homozygous for the same p.Val142Ile found in S1 and 
S2; this mutation segregated with the disease, being homozygous in affected family 
members (Figure. 1A). All the identified RNASEH1 variants were absent or extremely 
rare in public databases (<0.01% in ExAC; Table S3). 
All amino acid changes map to the first third of the RNAseH1 catalytic domain 
(Figure 2A). The p.Arg157* affects the 22nd residue of the catalytic domain predicting 
the synthesis of a truncated protein species lacking catalytic activity as proven by in 
vitro assay (see below). Substitutions p.Val142Ile and p.Ala185Val affect amino acids 
close to conserved residues, part of the active site or interacting with RNA or DNA 
strands (Figure 2A). 
RNASEH1 encodes mitochondrial and nuclear protein variants depending on which 
initiation AUG codons, encoding Met1 or Met27, are adopted. An upstream AUG, 
encoding Met0, competes with initiation at Met1, starting the mitochondrial variant, 
so that in physiological conditions the nuclear form, starting with Met27, is 
predominant6. An N-terminal MTS targets this protein to mitochondria, being 
eventually cleaved off by the mitochondrial matrix peptidase after translocation, 
resulting in a protein almost identical to the nuclear form. A second, exclusively 
nuclear ribonucleotidase activity on RNA:DNA hybrids is provided by RNAseH2, 
mutations in which are responsible of Aicardi-Goutieres syndrome [MIM 610333, 
610181]. To circumvent potential cross contamination and demonstrate the effect of 
the RNASEH1 mutations on protein activity, wild-type (wt) and mutant forms of 
mature human RNAseH1 were affinity-purified from overexpressing bacterial strains 
(Figures 1A and 1B). The in vitro activity of the recombinant proteins (Figure 2B) 
 was assessed on fluorescent-labeled oligos forming a 6 bp-long DNA:RNA 
heteroduplex (Figure S1B). Whilst the wt recombinant protein and E. coli RNaseH1 
were both able to fully cleave the RNA from the heteroduplex, the recombinant 
mutants p.Val142Ile and p.Ala185Val displayed partial activity, leaving significant 
amount of intact single-stranded and incompletely cleaved oligos, similar to those 
obtained by incubating the wt protein with the heteroduplex on ice. Similar to the 
negative “no protein” control, recombinant truncated protein p.Arg157* showed 
negligible activity, as did the p.Asp210Asn mutant, previously reported as 
catalytically inactive7 (Figure 2C).  
To further investigate the molecular consequences of RNASEH1 mutations, we 
characterized skin fibroblasts from S1 and two healthy control individuals, in 
permissive glycolytic-prone medium (containing glucose as the sole carbon source) or 
OXPHOS obligatory medium (containing galactose instead of glucose). RNASEH1 
transcript levels in S1 cells were decreased to 47% and 36% when grown in glucose 
or galactose, respectively (Figure S2), most likely due to nonsense-mediated mRNA 
decay of the transcript harbouring the premature stop codon. Western-blot analysis 
showed the virtual absence of the RNAseH1 protein in total S1 cell lysates (Figure 
3A) suggesting instability of both RNAseH1Arg157* and RNAseH1Val142Ile variants. 
Whilst glucose-grown cells showed no significant differences, S1 cells grew slower in 
galactose than control cells (Figure 3B), suggesting mitochondrial dysfunction. 
Accordingly, cell cycle analysis revealed significant increase in G1/G0 and decreased 
S phases in galactose-grown S1 cells (Figure S3). To further assess mitochondrial 
dysfunction, we analysed mitochondrial morphology and membrane potential (ΔP) on 
live cells using TMRM and JC-1 immunofluorescence (Figure 3C). Glucose-grown 
S1 cells displayed a mitochondrial network similar to that of control cells, albeit the 
 intensity of the staining was significantly lower, indicating reduced ΔP (Figures 3C 
and S4A). Flow-cytometry analysis using JC-1 staining showed 50% ΔP decrease in 
S1 cells (Figure S4B). Whilst galactose-grown control cells showed neither alteration 
in mitochondrial morphology nor ΔP changes, S1 cells displayed perinuclear 
aggregation of fragmented mitochondria, (Figure 3C) and higher ΔP (Figure S4B). 
To investigate the effect of RNASEH1 mutations on mtDNA, we first analysed 
nucleoid structure in live cells from control and S1 fibroblasts by PicoGreen staining. 
Glucose-grown S1 fibroblasts displayed fewer, smaller and sharper nucleoids (Figures 
3C and S5), whereas in galactose these differences were less prominent (Figure 3C), 
suggesting more active mtDNA metabolism in OXPHOS-obligatory conditions. Since 
PicoGreen staining is dependent on both amount and topology of mtDNA8, and we 
had observed mtDNA depletion in S2S2 myoblasts, we further investigated mtDNA 
copy number by Southern-blot analysis. S1 fibroblasts showed mild (-20%) mtDNA 
depletion only in glucose and no ΔmtDNA was detected (Figures 4A and 4B). These 
results were confirmed by qPCR (Figure S6). However, we observed a >tenfold 
increase in 7S DNA (Figure 4C), the third strand of the mtDNA displacement loop 
(D-loop); mutant muscle also displayed higher levels of 7S DNA (Figure 4D), 
suggesting aborted replication. 
Since these results indicated RNASEH1 mutations to affect mtDNA replication, we 
studied replication intermediates by two-dimensional gel electrophoresis9-11. Glucose-
grown S1 fibroblasts displayed a two- to four-fold increased signal compared to 
controls (Figures 5A-C and S7A). New replication intermediates, Y-arc extension, 
located at the end of the Y-arc pause, (Figures 5B and 5C), were detected in S1 
fibroblasts. This extension of the Y-arc may originate by the presence of persisting 
RNA between the light-strand promoter and the conserved-sequence-block 1 or 2 that 
 would be removed in control fibroblasts by a well proficient RNAseH1 (Figure 5D)11-
13. S1 fibroblasts also showed an increase in double-Y intermediates, indicating 
pausing at ribosomal genes, most likely owing to the failure of rRNA transcripts to be 
efficiently removed by mutant RNAseH1 (Figures 5B and 5D). Stronger signal in 
replication intermediates is consistent with replication slow-down, as also reported in 
MGME1 mutations4, and HEK cells overexpressing catalytic mutants of the mtDNA 
helicase or polymerase14. Galactose-grown cells showed decreased signal of almost all 
replication intermediates (Figure S7B). Finally, we performed mtDNA depletion and 
repopulation experiments. Glucose-grown cells exposed to the DNA intercalator EtBr 
for 96 hours, showed a decrease of mtDNA amount to <20% in all cell lines (Figure 
6A). Whilst control cells recovered to initial mtDNA levels in 120 hours, S1 cells 
required 168 hours, indicating slower replication rate. Mutations in other genes 
involved in mtDNA replication such as POLG1 [MIM 174763], RRM2B [MIM 
604712] and MGME1 have also been associated with slow or virtually no recovery in 
human fibroblasts4; 15. Active replication was measured as rate of BrdU incorporation 
in fibroblasts where nuclear replication was inhibited with aphidicolin (Figure 6B). S1 
fibroblasts showed 30% less BrdU incorporation than control cells in both glucose 
and galactose media, indicating slower mtDNA replication in S1 fibroblasts, most 
likely due to stalling caused by RNA tracts not being efficiently removed by mutant 
RNAseH113; 16. 
Our findings show that RNAseH1 is required for effective mtDNA replication in 
humans, as also suggested by embryolethality of an Rnaseh1-/- mouse model, which 
becomes virtually r0 by p.c. 8.518. Deleterious RNASEH1 mutations slow down and 
stall mtDNA replication, causing both mtDNA depletion and deletions and ultimately 
leading to clinically overt mitochondrial disease. Unlike MGME1, which is 
 exclusively mitochondrial, and similar to DNA2, RNAseH1 is localized in both 
nucleus and mitochondria. Nevertheless its impairment determines a virtually 
exclusively mtDNA damage, most likely because of the compensatory role of nuclear 
RNAseH2. All three enzymes are involved in maturation of mtDNA and possibly in 
its repair, although RNAseH1 seems to play a direct important role in mtDNA 
replication by processing the RNA primers of nascent strands. This could also explain 
the accumulation of 7S DNA species, as defective RNAseH1 increases the proportion 
of intermediates with the 7S RNA still attached to the nascent H strand. This kind of 
molecules is poorly processed by MGME14 and that could result in aborted 
replication. FENMIT is an exclusively mitochondrial isoform of FEN1 [MIM 
600393], that also interacts with RNA/DNA hybrids19. No mitochondrial diseases 
have been identified for FENMIT up to date and the degree of overlapping with 
RNAseH1 is not known. However, we could speculate that FENMIT could replace 
RNAseH1 in some instances and therefore, contributing to the mild phenotype in 
subjects with RNAseH1 mutations. According to the analysis of the replication 
intermediates by 2D-gel electrophoresis, mutant RNAseH1 is associated with 
increased pausing of the replication fork. Excessive pausing has been proposed as a 
mechanism leading to the accumulation of multiple deleted species and impairment of 
the replisome machinery either through breakage or recombination20,21, which may 
also explain partial mtDNA depletion and slower recovery of mtDNA copy number 
associated with RNASEH1 mutations.  	  
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Figure 1. Clinical, morphological and genetic features of individuals with 
mutations in RNASEH1.  
(A) Pedigrees of individuals with mutations in RNASEH1. Black symbols designate 
affected subjects, numbered according to the main text. The mutation status of all 
analysed family members is indicated, based on RNASEH1 RefSeq. 
(B) Brain MRI in subject 1. T1 sagittal (panel I) and cross (panel II) sections showing 
cerebellar atrophy and mild bulbar atrophy in S1. 
(C) Histological findings in subject 2 muscle biopsy: Cytochrome c oxidase (COX), 
succinate dehydrogenase (SDH), Gomori Trichrome (GT) staining showing 1 ragged-
red COX-/SDH+ fiber and several COX- fibers (Scale bars: 25µm). 
 (D) Electron microscopy with seamless mitochondrial network intermingled among 
myofibrils  in subject 2 (S2) muscle biopsy (Arrowheads indicate ramification of the 
mitochondrial syncytium. Scale bars: 0.25 µm upper panel; 0.10 µm lower panel). 
(E) Southern blot analysis of mtDNA obtained from muscle biopsies of affected 
individuals 1 and 5 (S1, S5), of control subjects (Ct) and of an individual with POLG1 
mutations (Ct+). 
(F) mtDNA levels assessed by qPCR in myoblasts from subject 2 (S2) and three 
controls (Ct). The mean value of the ratio mtDNA/nDNA obtained in controls was set 
as 1. Error bars represent standard deviations. 	  
  
Figure 2. Characterization of the structure and enzymatic activity of RNASEH1 
variants.  
(A) Human RNAseH1 (top) consists of four domains: a mitochondrial targeting 
sequence (MTS) that directs the protein to mitochondria and is cleaved after import, a 
hybrid binding domain (HBD) involved in recognition of DNA·RNA heteroduplexes, 
a catalytic domain responsible for the cleavage of the RNA component in the 
heteroduplex, and a flexible connection domain (CD) that links the last two domains. 
Phylogenetic alignment of the human protein region containing the substitutions 
found in affected individuals is shown below. Conserved residues mutated in affected 
subjects are boxed in red and are found near conserved residues in the active site or 
interacting with DNA or RNA in the heteroduplex, boxed in blue or green, 
 respectively. Hs, H. sapiens; Mm, M. musculus; Bt, B. taurus; Gg, G. gallus; Xl, X. 
laevis; Dr, D. rerio; Ci, C. intestinalis; Dm, D. melanogaster; Ce, C. elegans; Sc, S. 
cerevisiae.  
(B) RNAseH1 activity of recombinant proteins. The portion corresponding to the 
mature protein, lacking the mitochondrial targeting signal (MTS), was cloned into 
pET-28a bacterial expression vector (Novagen) which contains a N-terminal His6 tag. 
Protein expression was carried out in BL21(DE3)pLysS E. coli cells at 37ºC in LB 
medium. Proteins were loaded onto a Ni-NTA agarose column and eluted with 400 
mM imidazole. 80 nmoles of DNA·RNA heteroduplex oligo were incubated with 
either E. coli RNAseH1 or either wild type or mutant recombinant proteins for 1 
hour22. Reaction products were loaded onto 15% polyacrylamide gels followed by gel 
imaging and quantification. 
(C) Relative RNAseH1 activity was obtained by quantifying the amount of processed 
oligo normalized by protein loading (based on Western blotting, Supplementary Fig. 
1c) and relative to wild type protein. *P < 0.05, ***P < 0.001; two-tailed unpaired 
Student’s t test; n = 3; error bars = 1 s.d. 	  
  
Figure 3. Growth and mitochondrial alterations in RNASEH1 mutant 
fibroblasts.  
(A) Western Blot analysis of fibroblasts (fb) from affected subject 1 (S1) and controls 
(Ct) using antibodies against RNASEH1 (Abcam) and SDHA (Mitosciences-
Invitrogen); the latter was taken as a loading control. Both naïve and immortalized 
(Imm.) fibroblasts were used. 
(B) Growth curves of control and RNASEH1 S1 cells in glucose (high-glucose 
medium) and galactose (glucose-free medium supplemented with 50mM galactose). 
Cell growth was monitored continuously by IncuCyte live cell imager (Essen 
Bioscience). Data are shown as average and s.d. of three independent experiments. 
 (C) Mitochondria (red) were stained for 20 min with DP-dependent dye, TMRM (20 
nM), and DNA (green) with PicoGreen (3	µl/ml) in live cells grown in glucose or 
galactose for 5 days. Digitally enhanced TMRM image from RNASEH1 mutant 
fibroblasts from S1 is shown in Figure S4A.  	  
  
Figure 4. Mitochondrial DNA copy number and 7S DNA alterations in 
RNASEH1 mutant fibroblasts from S1 and muscle from S1 and S2.  
(A) Total DNA from control and RNASEH1 mutant fibroblasts was digested with 
PvuII and mtDNA was analysed by one-dimensional Southern blot. Radioactive 
probes specific for the human mtDNA D-loop region (nucleotide positions 16.341-
16.151, able to detect both linearised mtDNA and 7S DNA) and 18S ribosomal DNA 
were applied. 
(B) Relative mtDNA copy number (mtDNA/18S rDNA ratio) was obtained after 
quantification of the Southern-blot signal with PhosphorImager screens and 
normalization to control fibroblasts. ***P < 0.001; two-tailed Student’s t test; n = 2; 
error bars = 1 s.d.  
(C) 7S DNA levels (7S DNA/mtDNA ratio) were obtained after quantification of the 
Southern-blot signal with PhosphorImager screens and normalization to control 
fibroblasts. ***P < 0.001; two-tailed Student’s t test; n = 2; error bars = 1 s.d.  
 (D) 7S DNA levels (7S DNA/mtDNA ratio) in muscle from S1, S2 and subjects with 
mutations in MGME1 and DNA2 assessed by qPCR. 	  
  
Figure 5. Effect of mutant RNASEH1 fibroblasts from S1 on mtDNA replication. 
(A) Restriction enzyme sites and position of the probe are labeled. The origin of the 
H-strand replication (OH) is marked within the non-coding region (black bar). 
(B) mtDNA replication intermediates analysed by two-dimensional agarose gel 
electrophoresis (2D-AGE) and Southern bot. Explanatory cartoons are provided at the 
right of each image, with shades of gray reflecting the different intensities of the 
signal. 
(C) A cartoon based on this and previous work9-13 shows different replication 
intermediates associated to this fragment and the non-replicating fragment, 1n. 
(D) Proposed models that could explain the presence of a Y-arc extension (left) and 
increased double Y (right) mtDNA replication intermediates from RNASEH1 mutant 
fibroblasts from S1. Parental DNA strands are in black, nascent DNA strands in blue 
 and RNA in red. L-strand promoter (LSP) and conserved sequence block region 
(CSB) are marked as reference points.  	  
  
Figure 6. MtDNA replication is slowed down in mutant RNASEH1 fibroblasts 
from S1. 
(A) mtDNA copy number during depletion and recovery in control and RNASEH1 
mutant fibroblasts. Depletion was achieved by addition of 100 ng/ml EtBr to the 
culture medium for 96 h and recovery was followed up for 192 h after the removal of 
the drug. The mtDNA copy number was determined by qPCR, each data point 
representing the mean values from two independent determinations ± s.d. Arrowheads 
indicate the time point at which mtDNA was recovered at or close to initial values for 
each cell line. 
(B) Detection of newly synthesized mtDNA. Cells were treated with 20 µM 
Aphidicolin (Sigma) for six hours to block nuclear DNA replication. Total DNA from 
control and RNASEH1 mutant fibroblasts subjected to pulse-labeling of mtDNA with 
BrdU (100 µM) for 0, 1, 3, 6 and 24 h was digested with NaeI and analysed by one-
dimensional Southwestern blot. BrdU signal was immonodetected with anti-BrdU 
 antibody (Becton Dickinson) and was followed by mtDNA detection using a 
radioactive probe specific for the human mtDNA D-loop region. 
(C) Plot of BrdU incorporation over time, normalized to mtDNA loading; the linear 
regression for each cell line is shown. Each data point represents the mean of two 
replicates ± s.d. 	  
 Supplemental Case Reports 
 
Subject 1 
Subject 1 (S1) is a 42 year old male born after uncomplicated pregnancy and delivery, 
from healthy unrelated parents. He has two healthy daughters. His psychomotor 
development was normal. At 20 years of age he started complaining of muscle pain 
and at 21 he noticed eyelid ptosis associated with progressive ophthalmoplegia, 
occasional dysphagia, speech difficulties, and postural instability. At neurological 
examination he showed CPEO, dysarthria, dysphonia, wide-based gait, exercise 
intolerance with muscle cramps and weakness, particularly affecting the lower limbs. 
Neither hearing loss nor cardiac abnormalities nor diabetes were reported. Bilateral 
eyelid ptosis required surgery at the age of 32. At 36 he experienced recurrent 
episodes of ventilatory insufficiency including nocturnal dyspnoea and orthopnea; an 
acute episode required tracheostomy. He nevertheless recovered from this condition 
and later respiratory assessment disclosed only a mild restrictive deficit, without sleep 
apnoea, dyspnoea or orthopnea (average nocturnal oxygen saturation about 90%). 
ECG and Echocardiogram were normal. Laboratory tests showed high CK levels (400 
U/L; normal values, n.v. <195) and mild lactate increase (2856 µmol/L; n.v. 580-
2100). Brain MRI revealed moderate cerebellar and brain stem atrophy. A 
neurophysiologic assessment was performed: an Electromyography (EMG) showed 
mild motor demyelinating neuropathy prevalent in the lower limbs, eyelid and distal 
myopathic signs; Multimodal Evoked Potentials: multisystem CNS involvement with 
particularly altered Somatosensory evoked potentials (SEP) in the lower limbs. 
A muscle biopsy showed numerous ragged-red and COX negative fibres. Respiratory 
chain analysis performed on muscle tissue showed partial reduction of complex I and 
IV activity; the same analysis did not show alteration when performed on S1 skin 
fibroblasts. 
In the last few years, S1 experienced mild worsening of standing and gait stability, 
while muscle weakness and ventilatory impairment are stable. 
 
Subject 2 
Subject 2 (S2), a 46 year old man, is the second child of healthy non consanguineous 
parents. Family history was negative for neurological diseases; his motor 
 development was normal and he had a regular scholastic course. He had no 
neuromuscular abnormalities until 23 years of age, when he developed a progressive 
bilateral ptosis without diplopia. Neurological examination showed lateral and up 
gaze ophthalmoplegia, brisk reflexes with distal clonus and bilateral extensory plantar 
response. He referred fatigability, with no dyspnoea, dysphonia or dysphagia. The 
laboratory examination of plasma gave normal results with the only exception of 
increased lactate (30.8 mg/dl; n.v. 5.7-22 mg/dl). The EMG showed mild neurogenic 
signs; the EEG indicated generalized slow wave activity, with paroxysmal bilateral 
graphoelements, enhanced by hyperpnoea. An Echocardiogram (ECG) showed right 
bundle branch block pattern; fundus oculi and audiometry were normal. CSF 
investigation showed no pathological issues. MRI study was refused because of 
claustrophobia. Histological examination on biceps muscle biopsy displayed ragged 
red fibres (RRF) and absence of COX activity in several scattered fibres, many of 
which also showing intense SDH-positivity. Spectrophotometric analysis of MRC 
complex activities normalized to citrate synthase (CS) showed decreased cIV/CS ratio 
in muscle homogenate and in myoblasts (55% of control mean in both specimens), 
with partial reduction of cI+cIII/CS ratio (62%). Over the following 20 years, S2 
experienced worsening of ocular movements and muscle weakness. At the latest 
neurological examination (45 years of age) he presented severe gait impairment, 
being now unable to walk long distance, needing a wheelchair. Progressive head drop, 
dysphagia and trunk weakness had ensued. He also presented decreased visual acuity 
(5/10 right, 2/10 left), a complete ophthalmoplegia and profound weakness of 
orbicular oris and oculi muscles leading to corneal lesions with neovascularization. 
Other features included hypotrophy of interossei and thenar eminence, moderate limb 
(MRC 3-4/5) and marked axial muscle weakness (MRC 2-3/5), with tendency to 
propulsion of head and trunk. Mild cerebellar signs in the upper limbs were present; 
tendon reflexes were decreased, sensory examination showed isolated impairment of 
discriminative perception. Visual evoked potentials were undetectable. 
Electroretinogram showed reduction in amplitude. The subject developed arterial 
hypertension without respiratory and cardiologic involvement.  
 
Siblings S3-6 
 Subject 5 (S5) was born after uncomplicated pregnancy and delivery from healthy 
related parents. The same clinical phenotype was reported in three siblings (S3, S4, 
S6) while other four siblings were unaffected (Fig. 1a). She had two daughters and 
one son, all healthy. At 45 years old she started complaining of eyelid ptosis and 
ophthalmoparesis. The symptoms worsened progressively and she started presenting 
dysphonia, dysphagia leading to significant weight loss, and walking difficulties. The 
clinical examination at 48 years showed CPEO with paraparetic gait associated with 
pyramidal signs, and increased deep tendon reflexes. Some cerebellar signs were 
noticed such as dysmetria and a positive Romberg sign. Cognitive impairment and 
motor slowing were present. A brain MRI showed cerebellar and cortical atrophy with 
hyper-intense lesions in the deep periventricular white matter. She did not report 
hearing loss. The EMG pattern showed diffuse, proximal neuropathy. Cardiologic 
assessment was normal (ECG) at 48 years of age. CK levels were reported as normal. 
A muscle biopsy performed at the age of 48 showed ragged-red and COX negative 
fibres. She died at the age of 63 years for a sudden cardiac event. 
Her younger sister (S6), now aged 65, had a similar disease history. She started at 40 
years presenting with CPEO associated with progressive gait instability, severe 
dysphagia and ventilatory impairment. A muscle biopsy performed at 40 years 
showed mitochondrial myopathy (ragged red and COX negative fibers). She is now 
wheelchair bound, receives nutrients through a percutaneous endoscopic gastrostomy 
(PEG) and needs ventilatory support (non-invasive ventilation, NIV) during the day 
and oxygen administration during the night.  
A second sister (S4) died at 70 years because of respiratory failure and an older 
brother (S3) died at 60 years of unknown cause. Both were reported to have suffered 
of a similar condition with CPEO, dysphagia and respiratory impairment. 
 
 	  
 Figure S1: Recombinant RNAseH1 protein purification and in vitro assay 
 
 
 
(A) SDS-PAGE gel stained with Coomassie Brilliant Blue showing the protein profile 
of eluted fractions with 400 mM imidazole from the affinity purification of wt and 
mutant HIS.RNASEH1.HIS. The most intense protein bands (marked with 
arrowheads) of ~37 and ~21 kDa correspond to the purified HIS.RNASEH1.HIS 
protein. 
(B) In vitro assay for the measurement of RNAseH1 activity. A 5’ end Cy5.5 
fluorescently labelled chimeric oligo dA10A6dA10 was hybridised to an oligo dT26 and 
incubated at 37ºC for 1h. In the presence of active RNAseH1, the RNA component of 
the heteroduplex is cleaved. Then, loading buffer containing formamide was added 
and samples boiled at 85ºC for 5 min, and then cooled on ice before loading onto 15% 
polyacrylamide gels in 1xTBE. This will produce a processed fragment of shorter 
length but still labelled at the 5’ end and clearly distinguishable from the non-cleaved 
oligo used to form the heteroduplex. Control heteroduplex was not denatured before 
loading to avoid separation of the two strands and is loaded only as reference.  
(C) The identity of the purified proteins was confirmed by Western blotting with anti-
His antibody. These Western blots were also used as loading control for the 
normalization of the in vitro activity shown in Figure 1C. 	  
 Figure S2: RNASEH1 transcript levels  
 
 
 
Transcript levels were investigated with Life Technologies Gene Expression Assay 
(Hs00268000_m1) and normalized to GAPDH (Hs02758991_g1). Cells were grown 
in either glucose or galactose for five days. ***P < 0.001; two-tailed Student’s t test; 
n = 2; error bars = 1 s.d. 	  
 Figure S3: Cell cycle analysis  
 
 
 
Control and mutant fibroblasts grown in glucose or galactose for five days were 
subjected to cell cycle analysis using propidium iodine (left). The proportion of cells 
in sub G1/G0, G1/G0, S and G2/M phases was scored for each sample (right). **P < 
0.01, ***P < 0.001; two-tailed Student’s t test; n = 4; error bars = 1 s.d. 	  
 Figure S4: Mitochondrial membrane potential  
 
 
 
(A) TMRM staining of live cells grown in glucose for five days as shown in Figure 
2B was indicative of lower membrane potential in mutant fibroblast. However, the 
low signal did not allow a proper comparison of the mitochondrial morphology. 
Therefore, the signal has been two-fold enhanced in the RNASEH1 mutant fibroblasts 
in order to better appreciate the mitochondrial network. No significant difference 
compared to controls is observed. 
(B) Quantification of mitochondrial membrane potential in fibroblasts grown in 
glucose or galactose for five days using JC-1 staining. The ratio of red to green JC-1 
is plotted for the different samples as a measure of mitochondrial membrane potential. 
***P < 0.001; two-tailed unpaired Student’s t test; n = 4; error bars = 1 s.d. 	  
 Figure S5: Nucleoid measurements  
 
 
 
Nucleoid number (left) and size (right) were quantified in live cells grown in glucose 
or galactose for five days and stained with PicoGreen. Cells were imaged with a 
ZEISS ApoTome fluorescence microscope using a 40X immersion objective. 
Analysis was carried out using Particle Counting application available in ImageJ. **P 
< 0.01; ***P < 0.001; two-tailed Student’s t test; n = 10; error bars = 1 s.d. 	  
 Figure S6: Mitochondrial DNA copy number  
 
 
 
Relative mtDNA copy number was assessed in cells grown in glucose (top left) or 
galactose (bottom left) for five days by qPCR using Life Technologies Gene 
Expression Assays for four mitochondrial genes: COI (Hs02596864_g1), CYB 
(Hs02596867_s1), ND1 (Hs02596873_s1) and 12S rDNA (H202596859) and 
normalized to APP (Hs02339796_cn) levels. Control cells grown in glucose were 
arbitrarily chosen as reference and given value 1. Average of all four mitochondrial 
genes are shown on the right. *P < 0.05; ***P < 0.001; two-tailed unpaired Student’s 
t test; n = 4; error bars = 1 s.d. 	  
 Figure S7: Quantification of replication intermediates from 2D-AGE  
 
 
 
Replication intermediates and non-replicating mtDNA (1n) from cells growing in 
glucose or galactose for five days and shown in Figure 2A were quantified using 
ImageQuant software and normalized to the amount of non-replicating molecules (1n) 
for each sample. Control cells grown in glucose were arbitrarily chosen as reference 
and given value 1. ***P < 0.001; two-tailed unpaired Student’s t test; n = 2; error bars 
= 1 s.d.  	  
 Table S1: Functional variants number filtered by public databases. The functions of 
variants include missense, readthrough, nonsense, spliceSite, 5’-UTR and 3’-UTR. 	
Filter method Functional variants (SNP+InDel)* 
Before filtering  18,014+1,826 
Filtered by 1000 Genome variants database 1,808+519 
Filtered by 1000 Genome variants database_ 
HapMap 
1,333+308 
Filtered by 1000 Genome variants database_ 
HapMap_ESP 
1,317+308 
* SOAPaligner/SOAP2 (soap2.21) was use for mapping clean reads onto human 
reference genome (UCSC hg19, build 37.1), and SOAPsnp (v. 1.03) was used for SNP 
calling. BWA was used for mapping reads onto reference sequence in InDel analysis, 
and GATK (Genome Analysis Tool Kit) was used for InDel detection. 
 
 
 
Table S2: Prioritization of candidate genes	
Filter method Genes 
Recessive trait (≥2 variants/gene)  118 
Only coding and splice-site variants 26 
Predicted mitochondrial localization* 3 (AGXT, RNASEH1, TIMM23) 
* Maestro score >0 (www.broadinstitute.org) 
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Table S3: RNASEH1 mutations 
 
Subject DNA Protein Father/ Mother Exac frequency In vitro activity a  Mutation taster b Polyphen2 
c 
S1 c.424G>A p.Val142Ile F 0.00004963 40% Disease Damaging 
 c.469C>T p.Arg157* M 0.000008255 5% Disease / 
S2 c.554C>T p.Ala185Val F n.r. 20% Disease Damaging 
 c.424G>A p. Val142Ile M 0.00004963 40% Disease Damaging 
S3-6 c.424G>A p. Val142Ile F 0.00004963 40% Disease Damaging 
 c.424G>A p. Val142Ile M 0.00004963 40% Disease Damaging 
 
Nomenclature according to HGVS (NM_002936.4; NP_002927.2). F, father; M, 
mother. n.r.: not reported. a: compared to the activity of the wild-type enzyme. 
b: http://www.mutationtaster.org (Disease= disease causing) 
c: http://genetics.bwh.harvard.edu/pph2 (Damaging=probably damaging) 
 
 
 
 
